- Why Cryoport
- Who We Serve
- About Us
- News & Events
- Investor Relations
- Contact Us
Are your advanced therapy supply chains ready for this year’s 4G/LTE data management transition?
A leap forward in standardizing the regenerative medicine supply chain
In support of Cord Blood Awareness Month, Cryoport Systems’ partner, Be The Match BioTherapies®, led a webinar focused on the untapped potential and benefits of cord blood for prospective therapies. Cord blood is the blood that is leftover in the umbilical cord and placenta after birth, that contains life-saving stem cells with the potential to treat hematologic disorders in children and adults such as leukemia and lymphoma. Historically, the umbilical cord was discarded as medical waste, but cord blood has been used for over 30 years as one of the three cell sources for hematopoietic stem cell transplants, along with bone marrow and peripheral blood.
Although we are about to officially open our facilities, we have already received the first doses of a cell therapy from a clinical-stage biopharmaceutical company. The therapy will be used to treat clinical trial patients with advanced B-cell lymphoma and acute myeloid leukemia at clinics across the United States. The photos below shows our team in Morris Plains receiving the material recently.